EP0150184A1 - In vivo abbaubares polypeptid und dessen anwendung zur verzögerten freigabe von medikamenten - Google Patents

In vivo abbaubares polypeptid und dessen anwendung zur verzögerten freigabe von medikamenten

Info

Publication number
EP0150184A1
EP0150184A1 EP84901314A EP84901314A EP0150184A1 EP 0150184 A1 EP0150184 A1 EP 0150184A1 EP 84901314 A EP84901314 A EP 84901314A EP 84901314 A EP84901314 A EP 84901314A EP 0150184 A1 EP0150184 A1 EP 0150184A1
Authority
EP
European Patent Office
Prior art keywords
copolymer
polymer
acid
chosen
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP84901314A
Other languages
English (en)
French (fr)
Inventor
Daniel Bichon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Battelle Memorial Institute Inc
Original Assignee
Battelle Memorial Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Battelle Memorial Institute Inc filed Critical Battelle Memorial Institute Inc
Publication of EP0150184A1 publication Critical patent/EP0150184A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/10—Polyimides; Polyester-imides; Polyamide-imides; Polyamide acids or similar polyimide precursors
    • C08G73/1092—Polysuccinimides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A61L2300/604—Biodegradation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/29—Polyamino acid or polypeptide with an uninterrupted series of peptide repeating units

Definitions

  • the subject of the present invention is a novel biodegradable esterified polypeptide in which it is possible to incorporate medicaments, these being then gradually released progressively as the biochemical degradation of the polymer takes place.
  • non-toxic biodegradable polymers have been known which can serve as a reservoir of drugs and which allow the controlled gradual release of these into the body during the degradation of the carrier polymer.
  • General information on such products can be found in the book: "Fundamental Aspects of Biocompatibility" by D.F. WILLIAMS, CRC Press (1981). See also USP patent 4,093,709.
  • polyamino acids polyamino acids
  • these polypeptides are biocompatible and their degradation products (amino acids) are known to be absorbable by the body.
  • SIDMAN et al J. Mentor. Sci (1980), 7 (3), 277-91 have disclosed a copolymer of glutamic acid and ethyl ⁇ -glutamate, the degradation rate of which is a function of the composition of the copolymer (molar proportions of the esterified segments relative to the non-esterified segments) and which makes it possible to store numerous medicinal products, in particular steroids, peptides, anti-malaria, anti-cancer products and others.
  • Such polymers can be used in the form of rods containing, in a mixture, the desired medicament or in the form of capsules containing the medicament if the latter is not miscible with the polymer.
  • Thermoformability The synthetic polypeptides currently known are in fact generally not miscible with the usual biocompatible plasticizers (polyalkylene glycols) and, therefore, they are not thermoplastic.
  • R 1 and R 2 are alkyl groups or hydrogen with R a substituted or unsubstituted aliphatic or aromatic residue, or else R 2 is hydrogen or an alkyl and R 1 and R linked to one another are substituted or unsubstituted methylene or methenyl groups, n is 1 or 2 and x is such that the molecular mass is at least 5000 D.
  • the polymer of the invention is a polyaspartate or polyglutamate esterified by an acyloxymethanol derivative (HO-CR 1 R 2 -OOCR) in which R is either any organic residue or is linked to R 1 so as to form a cycle.
  • R acyloxymethanol derivative
  • any we mean that the nature and structure of the group R is not critical and that, for the moment, we have not encountered any case where, R being part of common compounds with RCOO- function, the corresponding component of the invention cannot be obtained. It is preferred, however, to use compounds in which R is a substituted or unsubstituted aliphatic or aromatic group, the substituents being chosen from organic functions biocompatible.
  • R groups Among the preferred R groups, mention may be made of methyl, ethyl, precyl, isopropyl, isobutyl, tert-butyl, phenyl, benzyl and other similar groups. Other compounds are naturally possible, but it is obvious that during the limited time available to the inventor he could not consider them all.
  • R and R 1 are linked together so as to produce a carbon-carbon bond, saturated or unsaturated, these carbon atoms may or may not be substituted by aliphatic or aromatic residues.
  • the polymer of the invention can also be in the form of a copolymer with other polyamino acids. In this case, there will be a copolymer of formula:
  • R is an amino acid esterified residue or not any
  • R ' is identical to the group - (CH 2 ) -COO-CR 1 R 2 -OOC-R, the n being however different (one of them being worth 1 and the other 2), one will have an esterified copolymer of glutamic acid and aspartic.
  • R ′ it is preferable for R ′ to have different groups, such as, for example methyl (alanine), iscprcpyle (valine), isobutyl (leucine and isoleucine), benzyl (phenylalaline), etc.
  • R 'can also denote a residue of glutamic or aspartic acid which is not esterified, or partially esterified by any alcohol, for example MeOH or EtOH, that is to say, for example - (CH 2 ) - n -COOH or - (CH 2 ) n -COOMe.
  • amino acids of the L or D series can also have, independently, amino acids of the L or D series.
  • the amino acids of the L (or natural) series is the most interesting because the polypeptides containing them are degradable by enzymes (proteases) of the human body, so that the polypeptides made up of D units are not. This difference can be exploited thanks to copolymers comprising amino acids D and L, this in order to have polymers whose degradation rate is modified.
  • the molar proportion, in copolymer II, of the other free or partially esterified polyamino acid also makes it possible, to a considerable extent, to regulate the rate of biodegradation of the copolymer as a function of the agents present in the organism at the site of destination of the mixture of copolymer and of the drug to be administered, (that is to say in the organ where the drug must act).
  • the copolymer is a copolymer of polyglutamate I and of leucine
  • the relative molar preparation of the two constituents will be chosen as a function of the relative rate of degradation, at the place considered, of the polyglutamate and of the polyleucine.
  • the z / y ratio can vary from 1 to 30, but these limits can be exceeded if necessary.
  • the group R ′ does not denote a group of unique nature in the chain of the copolymer, that is to say, for example, when one of the R ′ denotes an amino acid residue free and that another R 'denotes an esterified amino acid residue, it will be possible, for more convenience, to designate the variants of R' by the signs R '', R "', etc.
  • the general formula of such a copolymer can then be diagrammed as follows:
  • R can also influence the rate of degradation of the polymer I.
  • R is a bulky or hindered group (for example tert-butyl)
  • the degradation will be slower than with a methyl or ethyl group .
  • the polymers of the invention can comprise elements of configuration L or D or racemic mixtures or, again, polymers where one of the configurations dominates.
  • the biochemical properties of these various assemblies are, of course, not identical, the polymers in which the natural forms (L) dominate being more accessible to enzymatic degradation. We can therefore control its degradability by proportioning the relative proportions of one and the other form in the copolymer.
  • Polymers I and copolymer II are insoluble in water and generally soluble in one or more of the usual solvents such as acetone, methyl ethyl ketone (MEK), tetrahydrofuran (THF), dioxane, ethyl acetate , monoglyme, diglyme and others, which allows their easy transformation into beads, rods, fibers, filaments, microcapsules, films, etc.
  • Polymers I and II depending on their structure can be insoluble or soluble in chlorinated solvents, for example chloroform. In certain cases of insolubility in chloroform, this can be remedied if a little acetone is added to such a solvent.
  • polymer I is very often perfectly compatible with polyalkylene glycols (polyethylene glycol and polypropylene glycol), which makes it possible to use these polyether glycol as plasticizers for polymer I and thus to provide a homogeneous mixture of low Fusion point.
  • polyalkylene glycols polyethylene glycol and polypropylene glycol
  • thermolabile drugs One can easily incorporate a whole range of thermolabile drugs into such a mixture (melting at temperatures of the order of 40 to 60 ° C) and obtain granules or microcapsules.
  • highly hydrophilic polyalkylene glycols makes it possible to increase the susceptibility of the polymer and of the copolymer to aqueous biological liquids and facilitate their enzymatic degradation in situ.
  • Reaction (2) is consecutive to reaction (1) and, therefore, the biodegradation of the polymer will be all the faster the faster the hydrolysis rate of the lactal or acyloxyalkyl ester.
  • the hydrolysis mechanism of this type of ester is known per se and was highlighted during the study of ampicillin esters (for example pivampicillin), on this subject see the following reference: "Design of biopharmaceutical Properties through Prodrugs and Analogs ", B. Roche, editor, American Pharmaceutical Association (ISBN O-917330-16-1), pages 212 and 354 (1977).
  • the products resulting from the reaction when R and R 1 are linked to each other are also very advantageous because of their negligible toxicity.
  • the association R-R1 corresponds to the ethylene or 1,2-phenylene groups, the degradation products will be, respectively, 3-formyl-propionic and O-fo ⁇ ryl-benzoic acids slowly eliminated by the body without side reactions .
  • Polymer I can be prepared by direct esterification of a salt of the corresponding polyamino acid with an acyloxymethyl halide (X-CR 1 R 2 -COO-R (III)) or X can be chlorine, bromine or iodine .
  • the polyamino acid salt is preferably a tertiary amine salt (for example tributylamine or triethylamine). the such technique is known per se from WV DACHNE; J. Med. chem. 13, 607 - 12, 1971).
  • N-carboxyanhydride N-carboxyanhydride
  • the starting product which will be esterified with the compound XCR 1 R 2 -OCOR will be a copolymer of H 2 N-CH [(CH 2 ) n-COOH] - COOH and ester NH 2 -CH [(CH 2 ) n-COO Alk] -COOH.
  • Polymer I and copolymer II can be used as a drug reservoir in various ways.
  • the present polymers I and copolymers II can be used to make microcapsules containing a drug.
  • microcapsules comprise a polymeric membrane and contain an aqueous or oily solution in which the drug is in suspension or in solution.
  • Microspheres can also be made, that is to say solid particles or beads containing the drug in the dispersed state or in the form of a solid solution in the polymer matrix.
  • micro sponges microporous products
  • solubility of the present polymers in numerous solvents, miscible with water or not is an advantage for their application according to the techniques described in these references. It is also possible to prepare threads made of these polymers by extruding a solution of these in a die and precipitating the thread either by evaporation or by a bath of non-solvent, according to the usual spinning techniques. Filaments prepared in this way can be knitted, knotted or woven to form sutures, ligatures or tabular structures which can serve as artificial arteries, veins, conduits or internal organs temporarily functioning.
  • the polymers of the invention can also be used, either directly or as a mixture with a plasticizer, for the manufacture of films or surgical prostheses used, for example, in the consolidation of fractured bones, such as staples, needles, screws, reinforcement plates, buffers etc ..., these materials can be produced by casting or molding a solution, thermoforming or by machining solid polymer blocks. As such prostheses are absorbable, they are gradually eliminated in the body and it is then no longer necessary to provide, as is currently done, a new operation to remove the reinforcement and consolidation material.
  • composition of the polymer or copolymer used is to be adjusted, depending on the degradation rates and the absorption characteristics in vivo, depending on the nature of the prosthesis envisaged.
  • Example 1 illustrates the invention.
  • TFA trifluoroacetic acid
  • a molecular weight analysis was carried out by GPC (gel permeation chromatography) in DMF on a DUPONT ZORBAX PSM bimodal column (polystyrene calibration); an average molecular weight of Mn (number average molecular weight) of 226,000 was measured; and a dispersion (Mw / Mn) of 1.75.
  • This polymer is insoluble in water, CH 2 Cl 2 , CHCl 3 and ether; it swells without dissolving in methanol and ethanol; it dissolves easily in the following solvents: acetone, methyl ethyl ketone; THF, AcOEt DMF, TFA, dichloroacetic acid (DCA).
  • Thin polymer films can be prepared by spreading layers of these solutions on substrates and allowing them to evaporate.
  • Copolymer of partially methylated glutamic acid and pivaloyloxyethyl glutamate Copolymer of partially methylated glutamic acid and pivaloyloxyethyl glutamate.
  • This product very soluble in CHCI 3 , is insoluble in water, alcohol, polyethylene glycol and pure acetone. It is soluble in a mixture of acetone -CHCL 3 .
  • a dry film of a few ⁇ m of this polymer was prepared by means of a chloroform solution spread on a glass plate and evaporated. This film was placed in a container containing a 0.1N buffer solution at pH 9.5 and a slow degradation of the polymer was observed, which was observed, day after day, by increasing the UV absorption of the solution ( 280 nm) due to the presence of phthalide which gradually forms in the buffer solution.
  • microspheres dissolve in an isotermic medium (pH 7.5) and, over a prolonged period release the drug they contain, the rate of "release” varying according to their average size.
  • pH 7.5 isotermic medium
  • the action of the drug extends far beyond that of a conventional medication based on indomethacin.
  • TFA trifluoroacetic acid
  • the purity of the acid thus obtained was checked by NMR analysis in TFA (absence of the methyl ester band -O-CH 3 at 4.5 ppm.)
  • the polyacid was dissolved in DMF in an amount of 5% by weight and, to 50 ml of this solution, 4 ml of water and 4.04 g (0.04 mole) of triethylamine were added.
  • This polymer is insoluble in water, CH 2 Cl 2 , CHCI 3 and ether; it swells without dissolving in methanol and ethanol; it dissolves easily in the following solvents: acetone, methyl ethyl ketone; THF, AcOEt / DMF, TFA, dichloroacetic acid (DCA). Thin films of polymer can be prepared by spreading on substrates layers of these solutions and allowing them to evaporate. The IR spectrum also confirms the proposed structure (strong band at 1740 cm -1 ).
  • a thin film of the polymer obtained according to Example 6 was prepared by spreading a layer of 10% solution in acetone and allowing it to dry for a few hours at ordinary temperature in air.
  • Example 8 preparation of a pivaloyloxymethylglutamic ester and leucine copolymer.
  • Example 6 The procedure was as in Example 6, but starting from an 85/15 copolymer of polyglutamic acid and leucine and an 85/15 copolymer of pivaloyloxymethyl glutamate / leucine was obtained.
  • the NMR spectrum of the polymer in solution in the TFA shows that 100% of the lateral carboxylic groups of polyglutamic acid are esterified with chloromethylpivalate.
  • the polymer is also soluble in acetone, MEK, DMF, THF. It swells in alcohols, without dissolving.
  • Example 9 preparation of an isobutyloxymethylglutamate ester polymer. The synthesis was carried out starting from polyglutamic acid prepared as described in Example 6; this polymer was dissolved in DMF previously dried over a molecular sieve so as to obtain a 3.2% solution. To 20 g of this solution was added 1.83 g of tributylamine (2 equivalents). Contrary to what has been observed with triethylamine, it is not necessary to add water for the dissolution to take place. Then 1.36 g of isobutyric acid chloromethyl ester (prepared according to (ULICH, JACS 43, 662, (1921) (Eb.
  • the synthesis was carried out as in Example 9, but starting from chloromethylacetate.
  • the polymer obtained is also soluble in acetone. Its RHN spectrum shows the presence of a peak at 3.2 ppm, characteristic of the acetyl group (3 protons).
  • the polymer dissolves in aqueous caustic soda N / 100 by hydrolyzing in a few minutes.
  • Poly-pivaloyloxymethylglutamate the methyl group of which is labeled with 14C
  • chloromethylpivalate was synthesized by reacting pivaloyl chloride on paraformaldehyde labeled with 14C, according to the technique described in J.A.C.S., 89 (21), 5442, (1967).
  • the specific activity of the polymer, measured by combustion, is 3 ⁇ Cie / g.
  • Films of 3 x 3 cm were prepared with this polymer from solutions in acetone or in TFA. The films obtained are soaked either in enzymatic solutions of pig kidney leucineaminopeptidase (Sigma, 3.7 Units / ml, buffer 0.1 tris, 5 mM MgCl 2 , pH 8.4), or liver esterase from pork, (Sigma, 11.6 Units / ml, 0.1M Tris buffer, pH 7.5). The rate of degradation is measured by observing on the one hand the appearance of the polymer and, on the other hand, by counting the degree of radioactivity acquired by the solution. The enzyme solutions were renewed daily. The following results were obtained:
  • Poly-pivaloyloxymethyl glutamate is dissolved in acetone and 10% by weight of the polyethylene glycol 600 polymer is added. The solution is poured onto a Teflon plate and the solvent is allowed to evaporate. The film obtained is translucent and can be thermally welded around 120 ° C.
  • a copolymer of aspartic acid and leucine was prepared by copolymerizing ⁇ -benzylaspartate NCA and leucine NCA (N-carboxyanhydrides) in equimolecular proportions.
  • the benzyl ester groups are transesterified with methanol to obtain the poly- ( ⁇ -methylaspartate / leucine) copolymer.
  • the methylester groups are then saponified with N / 10 sodium hydroxide in methanol to obtain poly- (ASP (OH) / leu) acid.
  • Amino acid analysis shows that we have a proportion of leucine of 56% and 44% for aspartic acid.
  • the molecular weight M n is 35,000 (measured by GPC).
  • the polymer according to the invention (A) was converted into a film of about 0.25 mm by depositing on a glass plate a layer of acetone solution which was then subjected to evaporation in air. The same was done for the control film (B) from a solution in TFA acid. This last film was carefully washed with water to remove all traces of TFA.
  • Films (A) and (B) were immersed in aqueous solutions at pH 9.5 (phosphate buffer) with slow stirring and, at intervals, the radioactivity of the products dissolved in these solutions was measured, from which we calculated the hydrolysis rates of the polymers subjected to the test.
  • pH 9.5 phosphate buffer
  • the hydrolysis time can be varied, in the direction of an increase by increasing said rate and a decrease by reducing said rate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Polyamides (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
EP84901314A 1983-07-01 1984-04-02 In vivo abbaubares polypeptid und dessen anwendung zur verzögerten freigabe von medikamenten Pending EP0150184A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH3619/83 1983-07-01
CH361983 1983-07-01

Publications (1)

Publication Number Publication Date
EP0150184A1 true EP0150184A1 (de) 1985-08-07

Family

ID=4259870

Family Applications (2)

Application Number Title Priority Date Filing Date
EP84810156A Expired EP0130935B1 (de) 1983-07-01 1984-04-02 In-vivo abbaubares Polypeptid und dessen Anwendung zur verzögerten Freigabe von Medikamenten
EP84901314A Pending EP0150184A1 (de) 1983-07-01 1984-04-02 In vivo abbaubares polypeptid und dessen anwendung zur verzögerten freigabe von medikamenten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP84810156A Expired EP0130935B1 (de) 1983-07-01 1984-04-02 In-vivo abbaubares Polypeptid und dessen Anwendung zur verzögerten Freigabe von Medikamenten

Country Status (11)

Country Link
US (1) US4675381A (de)
EP (2) EP0130935B1 (de)
JP (1) JPS60501759A (de)
AT (1) ATE26584T1 (de)
AU (1) AU2698684A (de)
CA (1) CA1241322A (de)
DE (1) DE3463211D1 (de)
DK (1) DK88385D0 (de)
FI (1) FI73448C (de)
NO (1) NO850771L (de)
WO (1) WO1985000372A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
JPS60237015A (ja) * 1984-05-11 1985-11-25 Koken:Kk 医薬徐放剤
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
ATE60340T1 (de) * 1984-10-19 1991-02-15 Battelle Memorial Institute Durch mikroorganismen abbaubares polypeptid und seine verwendung fuer die fortschreitende abgabe von medikamenten.
US4863735A (en) * 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
CS252559B1 (en) * 1985-03-22 1987-09-17 Frantisek Rypacek Polymer stabilizer of emulsion type water in oil
US4895724A (en) * 1985-06-07 1990-01-23 Pfizer Inc. Chitosan compositions for controlled and prolonged release of macromolecules
CH667874A5 (fr) * 1985-12-19 1988-11-15 Battelle Memorial Institute Polypeptide synthetique biodegradable et son utilisation pour la preparation de medicaments.
IL78826A (en) * 1986-05-19 1991-05-12 Yissum Res Dev Co Precursor composition for the preparation of a biodegradable implant for the sustained release of an active material and such implants prepared therefrom
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
DE3700128A1 (de) * 1987-01-03 1988-07-14 Hoechst Ag Biologisch abbaubare poly- (hydroxyalkyl)- aminodicarbonsaeure-derivate, verfahren zu ihrer herstellung und verwendung derselben fuer depotzubereitungen mit kontrollierter wirkstoffabgabe
US4916204A (en) * 1987-07-31 1990-04-10 Massachusetts Institute Of Technology Pure polyanhydride from dicarboxylic acid and coupling agent
US5681543A (en) * 1988-02-29 1997-10-28 Shering Aktiengesellschaft Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI
GB8805286D0 (en) * 1988-03-05 1988-04-07 Schering Agrochemicals Ltd Trypanocides
US5023080A (en) * 1988-06-17 1991-06-11 Basic Bio Systems, Inc. Time release protein
US5700479A (en) * 1988-12-23 1997-12-23 Guidor Ab Surgical element and method for selective tissue regeneration
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
GB9107628D0 (en) 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
GB9204918D0 (en) * 1992-03-06 1992-04-22 Nycomed As Chemical compounds
FR2712892B1 (fr) * 1993-11-24 1995-12-22 Rhone Poulenc Chimie Procédé de préparation de polyimides ou de leurs hydrolysats biodégradables.
EP0659875B1 (de) * 1993-11-24 2001-08-08 Rhodia Chimie Verfahren zur Herstellung von Polyimiden oder ihren biologisch abbaubauren polypeptidischen Hydrolysaten
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
DE19545678A1 (de) * 1995-12-07 1997-06-12 Goldschmidt Ag Th Copolymere Polyaminosäureester
US6231888B1 (en) 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
WO1998030579A1 (en) * 1997-01-13 1998-07-16 Universite Laval Membrane-permeable derivatives converted intracellularly into active peptides
US6517869B1 (en) * 1997-12-12 2003-02-11 Expression Genetics, Inc. Positively charged poly(alpha-(omega-aminoalkyl)lycolic acid) for the delivery of a bioactive agent via tissue and cellular uptake
DE19822599C2 (de) * 1998-05-20 2003-02-06 Goldschmidt Ag Th Copolymere hydrophob modifizierte Polyasparaginsäureesteramide und ihre Verwendung
DE19822600C2 (de) * 1998-05-20 2003-08-21 Goldschmidt Ag Th Copolymere, hydrophob modifizierte Polyasparaginsäureester mit erhöhter Molekularmasse
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
CA2401327C (en) * 2000-03-03 2014-05-06 Valentis, Inc. Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use
AU2001266696A1 (en) 2000-06-02 2001-12-11 Bracco Research Usa Compounds for targeting endothelial cells
JP3819845B2 (ja) * 2001-04-06 2006-09-13 ブラッコ・リサーチ・ソシエテ・アノニム 流体で充填された空洞内の局所物理パラメータの改善された測定方法
AUPR610501A0 (en) * 2001-07-04 2001-07-26 Smart Drug Systems Inc Treatment of parasitic disease
US20030109432A1 (en) * 2001-12-10 2003-06-12 Zuo William W. Anticancer polypeptide-metal complexes and compositions, methods of making, and methods of using same
BRPI0314042B8 (pt) 2002-09-06 2021-05-25 Calando Pharmaceuticals Inc polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência
US20070128117A1 (en) * 2003-02-04 2007-06-07 Bracco International B.V. Ultrasound contrast agents and process for the preparation thereof
JP4670083B2 (ja) 2003-02-04 2011-04-13 ブラッコ・シュイス・ソシエテ・アノニム 超音波造影剤およびその製造方法
CN100563718C (zh) * 2003-12-22 2009-12-02 伯拉考开发股份有限公司 用于反差成像的充气微囊组件
US20060067972A1 (en) * 2004-06-23 2006-03-30 Flowmedica, Inc. Devices for renal-based heart failure treatment
US9248204B2 (en) * 2004-08-18 2016-02-02 Bracco Suisse S.A. Gas-filled microvesicles composition for contrast imaging
EP1714642A1 (de) 2005-04-18 2006-10-25 Bracco Research S.A. Pharmazeutische Formulierung mit gasgefüllten Mikrokapseln zur ultraschallgesteuerten Freisetzung
WO2007049770A1 (ja) 2005-10-28 2007-05-03 Meiji Seika Kaisha, Ltd. 緑膿菌の外膜タンパク質ｐａ５１５８
ATE465205T1 (de) * 2005-12-05 2010-05-15 Nitto Denko Corp Polyglutamat-aminosäure-konjugate und verfahren
AU2007232894B2 (en) 2006-03-30 2013-01-31 Meiji Seika Kaisha, Ltd. Pseudomonas aeruginosa outer membrane protein PA0427
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
JP2010526159A (ja) * 2007-04-10 2010-07-29 日東電工株式会社 多機能性ポリグルタミン酸塩薬物担体
CN101730549B (zh) * 2007-05-09 2015-12-09 日东电工株式会社 与铂类药物结合的聚合物
US20080279778A1 (en) * 2007-05-09 2008-11-13 Nitto Denko Corporation Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
PT2155255E (pt) 2007-05-09 2013-10-15 Nitto Denko Corp Composições que incluem um composto hidrofóbico e um conjugado de poliaminoácido
CA2691626A1 (en) * 2007-06-29 2009-01-08 Jiro Tanaka Pseudomonas aeruginosa-outer membrane protein pa4710
WO2009081955A1 (ja) 2007-12-25 2009-07-02 Meiji Seika Kaisha, Ltd. 緑膿菌のiii型分泌装置構成タンパク質pa1698
WO2009111271A1 (en) * 2008-03-06 2009-09-11 Nitto Denko Corporation Polymer paclitaxel conjugates and methods for treating cancer
CN102573884B (zh) * 2009-09-15 2015-01-14 阿洛莫恩临床有限公司 从蜘蛛毒液中分离的新型肽及其应用
AU2010321533A1 (en) * 2009-11-23 2012-05-31 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
US9789176B2 (en) 2011-03-16 2017-10-17 Regents Of The University Of Minnesota Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus
US20150147328A1 (en) 2012-05-07 2015-05-28 Mogam Biotechnology Institute Vaccine composition for preventing staphyllococcus aureus infection
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CN119185557A (zh) 2018-04-06 2024-12-27 阿玛治疗公司 用于控释治疗剂的组合物
WO2025132906A1 (en) 2023-12-22 2025-06-26 Bracco Suisse Sa Focused ultrasound thermal ablation with thermal enhancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3230274A (en) * 1960-12-30 1966-01-18 Merck & Co Inc Preparation of linear polypeptides
US3371069A (en) * 1963-03-20 1968-02-27 Ajinomoto Kk Filaments and surgical sutures of polyl-glutamic acid partly esterified with lower alkanols and process therefor
JPS5031905B1 (de) * 1971-07-05 1975-10-16
CA1045977A (en) * 1973-05-17 1979-01-09 Arthur D. Little Biodegradable, implantable drug delivery device, and process for preparing and using the same
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US4356166A (en) * 1978-12-08 1982-10-26 University Of Utah Time-release chemical delivery system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8500372A1 *

Also Published As

Publication number Publication date
AU2698684A (en) 1985-02-07
FI850835A0 (fi) 1985-02-28
NO850771L (no) 1985-02-26
CA1241322A (fr) 1988-08-30
FI73448C (fi) 1987-10-09
EP0130935B1 (de) 1987-04-15
WO1985000372A1 (fr) 1985-01-31
FI73448B (fi) 1987-06-30
DE3463211D1 (en) 1987-05-21
EP0130935A1 (de) 1985-01-09
ATE26584T1 (de) 1987-05-15
US4675381A (en) 1987-06-23
DK88385A (da) 1985-02-27
JPS60501759A (ja) 1985-10-17
FI850835L (fi) 1985-02-28
DK88385D0 (da) 1985-02-27

Similar Documents

Publication Publication Date Title
EP0130935B1 (de) In-vivo abbaubares Polypeptid und dessen Anwendung zur verzögerten Freigabe von Medikamenten
EP0179023B1 (de) Durch Mikroorganismen abbaubares Polypeptid und seine Verwendung für die fortschreitende Abgabe von Medikamenten
CH667874A5 (fr) Polypeptide synthetique biodegradable et son utilisation pour la preparation de medicaments.
SU905228A1 (ru) Способ получени полимочевины
EP1511790B1 (de) Alpha-tocopherol funktionalisierte polyaminosaüre und deren anwendungen, insbesondere im therapeutischen bereich
CA2302508C (en) Polyanhydrides with therapeutically useful degradation products
FR2551072A1 (fr) Nouveaux esters de polyols, leur preparation et leur utilisation
FR2741628A1 (fr) Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs
FR2537980A1 (fr) Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
EP1668062B1 (de) Mit hydrophoben gruppen telechelische funktionalisierte homopolyaminosäure und deren anwendungen, insbesondere im therapeutischen bereich
JP2003516810A (ja) 分解性ポリ（ビニルアルコール）ヒドロゲル
CA2408870A1 (fr) Materiau a base de polymeres biodegradables et son procede de preparation
EP0710226B1 (de) Neue reaktive thiol-gruppe enthaltende organische produkte, ein verfahren zu ihrer herstellung und sie enthaltende biomaterialien
FR2873704A1 (fr) Polyaminoacides fonctionnalises par des greffons hydrophobes portant une charge anionique et leurs applications notamment therapeutiques
EP0159293A1 (de) Filmbildendes, für Verbände verwendbares Polymermaterial und dessen Herstellung
FR2881140A1 (fr) Copolyhydroxyalkylglutamines fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
CN111410757B (zh) 一种可降解及环境响应性复合物微凝胶的制备方法
BE898430A (fr) Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation.
FR2873703A1 (fr) Polyaminoacides branches, fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
WO2010135739A2 (en) Poly(ester amide)s and poly(ester ether amide)s with pendant crosslinkable functional groups

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19850227

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 19860219

XX Miscellaneous (additional remarks)

Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 84810156.4/0130935 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 27.08.86.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BICHON, DANIEL